A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer's disease. The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nearly 30 LOAD susceptibility loci2-12 are known, and risk is significantly polygenic13.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“Recent sequencing studies identified a number of genes that have rare variants associated with AD9-11,18-24.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“The NH2-terminal APP A673T(Icelandic) mutation, however, makes APP a less favorable substrate for 𝛃 -secretase, resulting in decreased A 𝛃 production (299).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [299]
In the citing paper
“This observation is also true for the rare variant p.A673T (rs63750847) in APP, which was identified in Icelanders and was shown to have a strong protective effect against age-related cognitive decline as well as AD [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
In the citing paper
“The p.A673T variant was observed in control subjects aged over 85 years at a frequency of 0.45%, which is higher than that seen in AD patients [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
A new multipoint method for genome-wide association studies by imputation of genotypes
Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007) · Nature Genetics · doi:10.1038/ng2088 · Cited by 2,609
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
MDS Cognitive Performance Scale(C)
Morris, J. N., Fries, B. E., Mehr, D. R., Hawes, C., Phillips, C., Mor, V., & Lipsitz, L. A. (1994) · Journal of Gerontology · doi:10.1093/geronj/49.4.m174 · Cited by 1,810
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Cited by
Items 601–700 of 1,008
Mutation analysis of the MS4A and TREM gene clusters in a case-control Alzheimer's disease data set
Ghani, M., Sato, C., Kakhki, E. G., Gibbs, J. R., Traynor, B. J., George‐Hyslop, P. S., & Rogaeva, E. A. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.009 · Cited by 45
The past, present, and future of disease-modifying therapies for Alzheimer’s disease
Suzuki, K., Iwata, A., & Iwatsubo, T. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.048 · Cited by 48
Dysfunctional γ-Secretase in Familial Alzheimer’s Disease
Wolfe, M. S. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2511-1 · Cited by 51
“Recently, a protective mutation in this region was discovered, substantially reducing the risk of developing AD, even when carriers reach their 80s or 90s (Jonsson et al., 2012).”
Seki, T., Kanagawa, M., Kobayashi, K., Kowa, H., Yahata, N., Maruyama, K., Iwata, N., Inoue, H., & Toda, T. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008703 · Cited by 44
“In fact, the rare A673T mutation in APP, suppressing the β-cut and Aβ production by as much as 40%, is protective regarding the AD onset (40-42).”
Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease
Bera, A., Lavanya, G., Reshmi, R., Dev, K., & Kumar, R. K. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15611 · Cited by 45
Potential of tocotrienols in the prevention and therapy of Alzheimer's disease
Xia, W., & Mo, H. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.10.011 · Cited by 44
“[7] Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al.”
BackgroundInhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer’s Disease Cell Model
Liang, H., Shi, Y., Kou, Z., Peng, Y., Chen, W., Li, X., Li, S., Wang, Y., Wang, F., & Zhang, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140733 · Cited by 43
“A coding mutation in the APP gene (APPA673T) located at a site proximal to the BACE1 proteolytic site decreased BACE1 cleavage of APP and was protective against AD, which provides additional evidence that the inhibition of BACE1 cleavage of APP may protect against AD [8, 9].”
BackgroundPanza, F., Seripa, D., Lozupone, M., Solfrizzi, V., Imbimbo, B. P., Barulli, M. R., Tortelli, R., Capozzo, R., Bisceglia, P., Dimitri, A., et al. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389885 · Cited by 41
The Maze of APP Processing in Alzheimer’s Disease: Where Did We Go Wrong in Reasoning?
Chen, M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00186 · Cited by 47
“Also interesting is that a protective mutation has recently been found within the Swedish area (“Finnish mutation” A673T; Jonsson et al., 2012) (Figure 4).”
Considering a new paradigm for Alzheimer's disease research
Langley, G. R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.013 · Cited by 43
“68 Jonsson, T. et al. (2012) A mutation in APP protects against Alzheimer’s disease and”
Hunter, S., Arendt, T., & Brayne, C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8445-3 · Cited by 44
“associated with a lower risk of AD [237].”
BackgroundRetinal Toxicity Induced by a Novel β-secretase Inhibitor in the Sprague-Dawley Rat
Fielden, M. R., Werner, J., Jamison, J. A., Coppi, A., Hickman, D., Dunn, R. T., Trueblood, E., Zhou, L., Afshari, C. A., & Lightfoot-Dunn, R. (2015) · Toxicologic Pathology · doi:10.1177/0192623314553804 · Cited by 42
HSV, Axonal Transport and Alzheimer‘s Disease:in Vitro and in Vivo Evidence for Causal Relationships
Bearer, E. L. (2012) · Future Virology · doi:10.2217/fvl.12.81 · Cited by 41
“Conversely, a recent report from Iceland suggests that mutations that decrease but do not eliminate Aβ production have a strong protective effect against AD [108].”
BackgroundTajbakhsh, A., Read, M., Barreto, G. E., Ávila-Rodriguez, M., Gheibi-Hayat, S. M., & Sahebkar, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173873 · Cited by 41
The Inside-Out Amyloid Hypothesis and Synapse Pathology in Alzheimer's Disease
Gouras, G. K., Willén, K., & Faideau, M. (2014) · Neurodegenerative Diseases · doi:10.1159/000354776 · Cited by 42
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40
Tambini, M. D., Yao, W., & D'Adamio, L. (2019) · Aging Cell · doi:10.1111/acel.13033 · Cited by 40
“In contrast, humans car‐ rying the Icelandic APP variant, which codes for an APP protein that is inefficiently cleaved by BACE1, are protected from dementia and normal cognitive decline (Jonsson et al., 2012).”
BackgroundFactors Affecting Resilience and Prevention of Alzheimer's Disease and Related Dementias
Masurkar, A. V., Marsh, K., Morgan, B. E., Leitner, D., & Wısnıewskı, T. (2024) · Annals of Neurology · doi:10.1002/ana.27055 · Cited by 48
Khabirova, E., Moloney, A. M., Marciniak, S. J., Williams, J. H., Lomas, D. A., Oliver, S. G., Favrin, G., Sattelle, D. B., & Crowther, D. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102985 · Cited by 44
“Likewise, protection from AD has also been linked to a polymorphism in APP that interferes with bsecretase cleavage [10].”
BackgroundSoluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers
Perneczky, R., Alexopoulos, P., & Kurz, A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.10.001 · Cited by 46
Xie, B., Li, X., Dong, X., & Sun, Y. P. (2014) · Langmuir · doi:10.1021/la5025197 · Cited by 41
Melatonin receptor type 1A gene linked to Alzheimer’s disease in old age
Sulkava, S., Muggalla, P., Sulkava, R. O., Ollila, H. M., Peuralinna, T., Myllykangas, L., Kaivola, K., Stone, D. J., Traynor, B. J., Renton, A. E., et al. (2018) · SLEEP · doi:10.1093/sleep/zsy103 · Cited by 40
“In addition, previously, when using cognitively intact and old (> 85 years) “supercontrols,” stronger effect size was reported in the Icelandic population for a putative protective variant, A673T substitution of APP [48], and for a risk variant rs75932628-T of TREM2 [49].”
BackgroundPredicted loss and gain of function mutations in ACO1 are associated with erythropoiesis
Oskarsson, G. R., Oddsson, Á., Magnússon, M. K., Kristjansson, R. P., Halldorsson, G. H., Ferkingstad, E., Zink, F., Helgadóttir, A., Ivarsdottir, E. V., Arnadottir, G. A., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0921-5 · Cited by 43
Self-citationLiu, L., Lauro, B. M., Wolfe, M. S., & Selkoe, D. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100393 · Cited by 40
“Analogous to how carriers of the Icelandic (A673T) APP mutation have a reduced risk for AD (32), we speculate that mutations in a GxxxG motif, such as our G29A, could serve as another way to lessen Aβ deposition and thus subsequent neurodegeneration and dementia.”
BackgroundLo, A. C., Evans, C. D., Mancini, M., Wang, H., Shcherbinin, S., Lu, M., Natanegara, F., & Willis, B. A. (2021) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210296 · Cited by 39
“The lower spectrum of BACE inhibition, such as in the range of amyloidogenic peptide reduction, 30–40%, similar to the Icelandic mutation [37], was not explored.”
BackgroundAlzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
Alawode, D. O. T., Fox, N. C., Zetterberg, H., & Heslegrave, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.837390 · Cited by 45
Challenge accepted: uncovering the role of rare genetic variants in Alzheimer’s disease
Khani, M., Gibbons, E., Bras, J., & Guerreiro, R. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00505-9 · Cited by 39
“Additionally, the protective allele was found to be associated with increased performance on cognitive tests in elderly cognitively normal participants, suggesting the protective effect of the variant is not limited to AD pathogenesis but also affects cognition in individuals within the healthy spectrum of aging [74].”
BackgroundInfluentialNew Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease
Penke, B., Szűcs, M., & Bogár, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065383 · Cited by 44
“(Interestingly, a protective mutation of APP that decreases Aβ aggregation was found in the Iceland population [25]).”
BackgroundA task force for diagnosis and treatment of people with Alzheimer’s disease in Latin America
Lopera, F. J., Custodio, N., Rico-Restrepo, M., Allegri, R., Barrientos, J. D., Batres, E. G., Calandri, I. L., Moscoso, C., Caramelli, P., Quiroz, J. C. D., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1198869 · Cited by 47
“Includes the e2 variant of APOE (136), mutation A673T in PPA (137), the Christchurch mutation (R136S) in ApoE3 (138), the V236E variant in 22 APOE 3, and the R251G variant in APOE 4 (139).”
BackgroundInfluentialSchindler, S. E., & Fagan, A. M. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00142 · Cited by 45
“In further support of this hypothesis, amutationwas recently discovered in APP that decreases Aβ production and lowers the risk for AD (42).”
BackgroundCNS Amyloid- , Soluble APP- and - Kinetics during BACE Inhibition
Dobrowolska, J. A., Michener, M. S., Wu, G., Patterson, B. W., Chott, R., Ovod, V., Pyatkivskyy, Y., Wildsmith, K. R., Kasten, T., Mathers, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0540-14.2014 · Cited by 37
Liu, Y.-W., He, Y.-H., Zhang, Y.-X., Cai, W.-W., Yang, L.-Q., Xu, L.-Y., & Kong, Q.-P. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.023 · Cited by 39
Self-citationEketjall, S., Janson, J., Jeppsson, F., Svanhagen, A., Kolmodin, K., Gustavsson, S., Radesater, A.-C., Eliason, K., Briem, S., Appelkvist, P., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1165-13.2013 · Cited by 39
Core Refinement toward Permeable β-Secretase (BACE-1) Inhibitors with Low hERG Activity
Ginman, T., Viklund, J., Malmström, J., Blid, J., Emond, R., Forsblom, R., Johansson, A., Kers, A., Lake, F., Sehgelmeble, F. W., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3011349 · Cited by 41
Amyloid β Fibril Elongation by Monomers Involves Disorder at the Tip
Bacci, M., Vymětal, J., Mihajlovic, M., Caflisch, A., & Vitalis, A. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.7b00662 · Cited by 41
Karch, S., Broichhagen, J., Schneider, J., Böning, D., Hartmann, S., Schmid, B., Tripal, P., Palmisano, R., Alzheimer, C., Johnsson, K., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00387 · Cited by 41
Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases
Sarnataro, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103081 · Cited by 40
“In contrast, a rare mutation in an APP gene (APPA673T) reduces both the production of Aβ and its tendency to aggregate [52].”
BackgroundCombination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force
Gauthier, S., Alam, J., Fillit, H., Iwatsubo, T., Liu-Seifert, H., Sabbagh, M., Salloway, S., Sampaio, C., Sims, J. R., Sperling, B., et al. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.12 · Cited by 37
“In addition, a mutation in the APP gene known as the Icelandic mutation (A673T) has been shown to be protective against AD and cognitive decline (11).”
BackgroundBlood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease
Šimić, G., Španić, E., Horvat, L. L., & Hof, P. R. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.003 · Cited by 41
Pousinha, P. A., Mouska, X., Bianchi, D., Temido‐Ferreira, M., Rajão‐Saraiva, J., Gomes, R., Fernández, S. P., Pereira, A. R. S., Gandin, C., Raymond, E., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.103 · Cited by 43
“Human genetic evidence indicates that the amyloid precursor protein (APP) is central to the pathogenesis of AD (Jonsson et al., 2012; van der Kant and Goldstein, 2015).”
BackgroundAnalysis of neurodegenerative disease-causing genes in dementia with Lewy bodies
Orme, T., Hernandez, D., Ross, O. A., Kun-Rodrigues, C., Darwent, L., Shepherd, C. E., Parkkinen, L., Ansorge, O., Clark, L., Honig, L. S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0879-z · Cited by 41
“Adjacent amino acid plays a role in disease [22, 32]”
Backgroundde la Vega, M. P., Giedraitis, V., Michno, W., Kilander, L., Güner, G., Zielinski, M., Löwenmark, M., Brundin, R., Danfors, T., Söderberg, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc6184 · Cited by 47
Mukherjee, S., Russell, J. C., Carr, D. T., Burgess, J. D., Allen, M., Serie, D. J., Boehme, K. L., Kauwe, J. S. K., Naj, A. C., Fardo, D. W., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.016 · Cited by 39
“One rare variant in APP was found to be protective for LOAD in Iceland [36]; this variant is rare in North Americans [37] and does not explain our findings, which are derived from variants with minor allele frequency.”
BackgroundEitan, C., Siany, A., Barkan, E., Olender, T., van Eijk, K. R., Moisse, M., Farhan, S. M. K., Danino, Y. M., Yanowski, E., Marmor-Kollet, H., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01040-6 · Cited by 38
Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease
Lambracht‐Washington, D., & Rosenberg, R. N. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s31428 · Cited by 47
“The APP substitution A673T is adjacent to the β-secretase cleavage site, leading to a 40% reduction in overall Aβ42 levels.(27) These Im m un oT ar ge ts a nd T he ra py d ow nl oa de d fr om h ttp s: //w w w .”
Sadleir, K. R., Eimer, W. A., Kaufman, R. J., Osten, P., & Vassar, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101643 · Cited by 36
“Recently, a mutation in APP near the BACE1 cleavage site (A673T) was identified that protects against AD by reducing BACE1 cleavage of APP and Ab production [18].”
BackgroundThomas, A. A., Hunt, K. W., Volgraf, M., Watts, R. J., Liu, X., Vigers, G. P. A., Smith, D. J., Sammond, D. M., Tang, T. P., Rhodes, S. P., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401635n · Cited by 44
Self-citationNIAGADS: The NIA Genetics of Alzheimer's Disease Data Storage Site
Kuzma, A. B., Valladares, O., Cweibel, R., Greenfest‐Allen, E., Childress, D. M., Malamon, J. S., Gangadharan, P., Zhao, Y., Qu, L., Leung, Y. Y., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.08.018 · Cited by 42
“Rare protective [3] and susceptibility variants [4] were also found by genome resequencing.”
BackgroundJurcau, A., & Simion, A. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200303121016 · Cited by 38
Mechanisms of neuronal survival safeguarded by endocytosis and autophagy
Overhoff, M., Bruyckere, E. D., & Kononenko, N. L. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15194 · Cited by 46
“It is well established that the increased amyloidogenic processing of amyloid precursor protein (APP), resulting in augmented production of Amyloid-β (Aβ) is a key feature underlying the pathogenesis of AD (Haass & Selkoe, 2007; Hardy & Selkoe, 2002; Jonsson et al., 2012).”
BackgroundLifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimer's Disease
Gandy, S. (2012) · New England Journal of Medicine · doi:10.1056/nejme1207995 · Cited by 39
Metabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer's disease
Caraci, F., Nicoletti, F., & Copani, A. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.12.001 · Cited by 37
“A counterexample exists of a rare genetic mutation that reduces the risk of developing AD by altering the coding sequence of Ab and reducing Ab production [4].”
BackgroundAPP dyshomeostasis in the pathogenesis of Alzheimer’s disease: implications for current drug targets
Sirisi, S., Sánchez‐Aced, É., Belbin, O., & Lleó, A. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01504-w · Cited by 43
“The main mechanism by which these genetic alterations cause AD is believed to be a total or relative increase in the production of Aβ42 or an increase in the propensity to aggregate [8].”
Backgroundβ‐Amyloid pathogenesis: Chemical properties versus cellular levels
Tiwari, M. K., & Kepp, K. P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1895 · Cited by 37
Can insulin signaling pathways be targeted to transport Aβ out of the brain?
Vandal, M., Bourassa, P., & Calon, F. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00114 · Cited by 41
“…risk of AD (Goate et al., 1991; Rogaev et al., 1995; Sherrington et al., 1995; Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997), while a mutation more recently found to reduce Aβ production was rather associated with reduced AD incidence (Jonsson et al., 2012).”
Gene panels and primers for next generation sequencing studies on neurodegenerative disorders
Giau, V. V., An, S. S. A., Bagyinszky, E., & Kim, S. (2015) · Molecular & Cellular Toxicology · doi:10.1007/s13273-015-0011-9 · Cited by 40
Application of yeast to studying amyloid and prion diseases
Chernoff, Y. O., Grizel, A. V., Rubel, A. A., Zelinsky, A. А., Chandramowlishwaran, P., & Chernova, T. A. (2020) · Advances in genetics · doi:10.1016/bs.adgen.2020.01.002 · Cited by 46
“A substitution at aa position 2 of the Aβ sequence, that is frequently found in the population of Iceland, leads to a decrease in both Aβ levels and incidence of sporadic AD, as well as to an increase of life span (Jonsson et al., 2012).”
BackgroundEmerging genetic complexity and rare genetic variants in neurodegenerative brain diseases
Perrone, F., Cacace, R., van der Zee, J., & Van Broeckhoven, C. (2021) · Genome Medicine · doi:10.1186/s13073-021-00878-y · Cited by 38
“Some missense mutations are present only in healthy controls [89] and are a powerful tool to investigate protective biological processes that might slow disease progression and in developing new therapeutic strategies.”
BackgroundTremblay, G., Rousseau, J., Mbakam, C. H., & Tremblay, J. P. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0085 · Cited by 40
“22–24 Because the cells used in the current experiments are wild type, we have shown that it is possible to induce the mutation responsible for the V717I form of AD.”
BackgroundInfluentialWakhloo, D., Mahajani, S. U., Oberhauser, J., & Madira, A. E. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.336138 · Cited by 42
“Petersen, 2018; Roehr et al., 2020), A673T (Peacock et al., 1993; Jonsson et al., 2012), and KM670/671NL (Oksanen et al., 2018) have given to the amyloid cascade hypothesis, which states that an imbalance in APP metabolism leads to altered Aβ homeostasis, triggering AD-type neurodegeneration (Uddin…”
Filling the void: a role for exercise-induced BDNF and brain amyloid precursor protein processing
MacPherson, R. E. K. (2017) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00255.2017 · Cited by 44
“In addition, humans with an APP mutation that effects the -cleavage site (50) and mice with a targeted deletion of BACE1 (64, 94) are protected from -amyloid peptide formation, thus providing strong evidence in support of the concept that BACE1 reduction or inhibition could be efficacious for the treatment of AD.”
BackgroundAlzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention
Rafii, M. S., & Aisen, P. S. (2019) · CNS Drugs · doi:10.1007/s40263-018-0598-1 · Cited by 36
Krstic, D., & Knuesel, I. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-62 · Cited by 35
“Interestingly, a recently discovered “protective” muta- tion in APP (APPA673T) [67] results not only a delay of the onset of AD, but also in better cognitive performance of AD patients that carry the mutation.”
BackgroundInfluentialThe 5-Lipoxygenase as modulator of Alzheimer’s γ-secretase and therapeutic target
Chu, J., & Praticò, D. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.010 · Cited by 38
“However, some recent clinical data have also found mutations in the APP gene that are protective and reduce the risk to develop the disease [4].”
Kajiwara, Y., McKenzie, A. T., Dorr, N. P., Sosa, M. A. G., Elder, G. A., Schmeidler, J., Dickstein, D. L., Bozdagi, O., Zhang, B., & Buxbaum, J. D. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw265 · Cited by 45
Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease
Tomita, T. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.01.001 · Cited by 37
Biological basis for amyloidogenesis in Alzheimer’S disease
Andreeva, T. V., Lukiw, W. J., & Rogaev, E. I. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917020043 · Cited by 36
“AD pro tective mutation A673T has been found at the same codon of the APP gene [62].”
Fuchino, K., Mitsuoka, Y., Masui, M., Kurose, N., Yoshida, S., Komano, K., Yamamoto, T., Ogawa, M., Unemura, C., Hosono, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00002 · Cited by 38
Nakahara, K., Fuchino, K., Komano, K., Asada, N., Tadano, G., Hasegawa, T., Yamamoto, T., Sako, Y., Ogawa, M., Unemura, C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00011 · Cited by 40
APLP1 is endoproteolytically cleaved by γ-secretase without previous ectodomain shedding
Schauenburg, L., Liebsch, F., Eravci, M., Mayer, M. C., Weise, C., & Multhaup, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-19530-8 · Cited by 36
Therapeutic strategies for targeting neurodegenerative protein misfolding disorders
Scannevin, R. H. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.018 · Cited by 42
Pettus, L. H., Bourbeau, M. P., Bradley, J., Bartberger, M. D., Chen, K., Hickman, D., Johnson, M., Liu, Q., Manning, J. R., Nañez, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01034 · Cited by 37
Kaur, G., & Prakash, A. K. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.108255 · Cited by 41
Wallin, C., Friedemann, M., Sholts, S. B., Noormägi, A., Svantesson, T., Jarvet, J., Roos, P. M., Palumaa, P., Gräslund, A., & Wärmländer, S. K. T. S. (2019) · Biomolecules · doi:10.3390/biom10010044 · Cited by 42
Caselli, R. J., Knopman, D. S., & Bu, G. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12124 · Cited by 38
Targeting epigenetics: A novel promise for Alzheimer’s disease treatment
Jeremic, D., Jiménez‐Díaz, L., & Navarro‐López, J. D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102003 · Cited by 39
Rare and low-frequency variants in human common diseases and other complex traits
Lettre, G. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102437 · Cited by 43
N-Terminal Hypothesis for Alzheimer’s Disease
Murray, B., Sharma, B., & Belfort, G. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00037 · Cited by 36
Promising Targets for the Treatment of Neurodegenerative Diseases
Budd Haeberlein, S., & Harris, T. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.195 · Cited by 35
Svedružić, Ž. M., Popović, K., & Jengić, V. Š. (2013) · PLoS ONE · doi:10.1371/journal.pone.0050759 · Cited by 42
“On the other hand, decrease in the extent of c-secretase saturation with its C99 substrate can decrease the chances of pathogenesis [61].”
BackgroundRahman, M. A., Abdullah, N., & Aminudin, N. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1100585 · Cited by 37
“Modification of the BACE1-mediated APP-cleavage results in altered AD pathology (Jonsson et al., 2012).”
BackgroundGenetics of Chronic Traumatic Encephalopathy
Abdolmohammadi, B., Dupre, A., Evers, L., & Mez, J. (2020) · Seminars in Neurology · doi:10.1055/s-0040-1713631 · Cited by 37
Adeno‐associated virus‐based Alzheimer's disease mouse models and potential new therapeutic avenues
Ittner, L. M., Klugmann, M., & Ke, Y. D. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14637 · Cited by 39
“An exception to this is the A673T point mutation identified mainly in Icelandic and Scandinavian populations that reduces the formation of Aβ as well as the prevalence of AD (Jonsson et al., 2012).”
BackgroundNew Insights into the Molecular Bases of Familial Alzheimer’s Disease
D’Argenio, V., & Sarnataro, D. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10020026 · Cited by 44
“, identified a rare APP variant in the Icelandic population showing a protective effect [37].”
BackgroundBerman, D. E., Ringe, D., Petsko, G. A., & Small, S. A. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0321-y · Cited by 35
“This novel class of retromer chaperones can, in principle, traffic APP away from a pathogenic towards a nonpathogenic processing pathway, generating a profile of proteolytic fragments that mimics a fragment profile generated by a mutation in APP shown to be protective against AD [20].”
BackgroundDrugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?
Kakish, J., Lee, D., & Lee, J. S. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00172 · Cited by 39
Molecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease
Żukowska, J., Moss, S. J., Subramanian, V., & Acharya, K. R. (2023) · FEBS Journal · doi:10.1111/febs.16939 · Cited by 44
“Some missense mutations in the APP gene can also result in reduced A b production and provide a protective function against AD [17].”
Vingtdeux, V., Chandakkar, P., Zhao, H., Blanc, L., Ruiz, S., & Marambaud, P. (2015) · Journal of Cell Science · doi:10.1242/jcs.167270 · Cited by 39
Awasthi, M., Singh, S., Pandey, V. P., & Dwivedi, U. N. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1279078 · Cited by 34
“Authors demonstrated that the A2T substitution resulted in a reduced cleavage of APP by β-secretase as compared to WT APP, leading to ∼40% less formation of Aβ in homozygous carriers while this decrease in Aβ production was reported to be moderate 20% in heterozygous carriers (Jonsson et al., 2012).”
BackgroundDysregulated Metabolism of the Amyloid‐β Protein and Therapeutic Approaches in Alzheimer Disease
Kikuchi, K., Kidana, K., Tatebe, T., & Tomita, T. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26129 · Cited by 40
“On the other hand, the A673T mutation in the APP gene identified from the Iceland population is located in the vicinity of the cleavage site of β-secretase, and decreases total Aβ production as well as the risk of AD [Jonsson et al., 2012].”
BackgroundPradier, L., Blanchard-Brégeon, V., Bohme, A., Debeir, T., Ménager, J., Benoit, P., Barnéoud, P., Taupin, V., Bertrand, P., Dugay, P., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0447-y · Cited by 39
“Genetic evidence supports the key role of amyloid β (Aβ) peptide in the pathogenesis of AD: 1) all mutations causing familial AD increase the production of Aβ42 or the ratio of Aβ42 to the less aggregation-prone Aβ40 form [2]; and 2) genetic variants that reduce Aβ production lower the risk of developing AD [3].”
BackgroundManchanda, S., Galan-Acosta, L., Abelein, A., Tambaro, S., Chen, G., Nilsson, P., & Johansson, J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.010 · Cited by 38
Crown ethers attenuate aggregation of amyloid beta of Alzheimer's disease
Tian, Y., Zhang, X., Li, Y., Shoup, T. M., Teng, X., Elmaleh, D. R., Moore, A. V., & Ran, C. (2014) · Chemical Communications · doi:10.1039/c4cc06029f · Cited by 36
Tackling amyloidogenesis in Alzheimer’s disease with A2V variants of Amyloid-β
Fede, G. D., Catania, M., Maderna, E., Morbin, M., Moda, F., Colombo, L., Rossi, A., Cagnotto, A., Virgilio, T., Palamara, L., et al. (2016) · Scientific Reports · doi:10.1038/srep20949 · Cited by 36
Aisen, P. S. S., Bateman, R. J., Crowther, D. C., Cummings, J., Dwyer, J. R., Iwatsubo, T., Kosco‐Vilbois, M. H., McDade, E., Mohs, R. C., Scheltens, P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14342 · Cited by 38
“26 For example, one such mutation carrier survived to age 104 with no AD symptoms and was found to have very little amyloid deposition upon autopsy.”
Gozes, I., Yeheskel, A., & Pasmanik‐Chor, M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142490 · Cited by 35
“Our analysis takes a rather limited look at AD with tau (forming the neurofibrillary tangles) [22], amyloidprotein precursor (A PP, with amyloid- peptide forming the plaques, mutated in familial AD and also presenting mutations protecting against AD [56]), Presenilin (Psen1), associated with A PP processing and also m…”
BackgroundAdditional mechanisms conferring genetic susceptibility to Alzheimer’s disease
Calero, M., Gómez‐Ramos, A., Calero, O., Soriano, E., Ávila, J., & Medina, M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00138 · Cited by 45
Wang, J., Yu, J., & Tan, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8779-5 · Cited by 41
Bamne, M. N., Demirci, F. Y., Berman, S., Snitz, B. E., Rosenthal, S. L., Wang, X., López, O. L., & Kamboh, M. I. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.020 · Cited by 35
Identification of rare variants in Alzheimer’s disease
Lord, J., Lu, A. J., & Cruchaga, C. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00369 · Cited by 33
“APP (PROTECTIVE) With APP as a clear biological candidate for involvement in AD risk, Jonsson et al. (2012) sought low frequency and rare mutations in whole genome sequence from 1795 Icelanders, and imputed recurrent variants in 71,743 chip-genotyped Icelanders and 296,496 relatives of genotyped…”
BackgroundInfluential
Metadata
- Authors
- Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jönsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., & Stefansson, K.
- Affiliations
- Genentech (US)
- deCODE Genetics (Iceland) (IS)
- University of Oslo (NO)
- Karolinska Institutet (SE)
- University of Helsinki (FI)
- ORCID
- Venue
- Nature
- Published
- 2012-07-11
- Volume
- 488
- Issue
- 7409
- Pages
- 96-99
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2154755614
- Cited by
- 1,738
- References
- 26
- Citations by year
- 2026: 56 · 2025: 72 · 2024: 93 · 2023: 94 · 2022: 70 · 2021: 120 · 2020: 134 · 2019: 107 · 2018: 134 · 2017: 145 · 2016: 155 · 2015: 166 · 2014: 173 · 2013: 154 · 2012: 60
- FWCI
- 119.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-102924, HL-102925, HL 103010, HL-102926)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, amyloid precursor protein, APP gene, protective genetic variants, cognitive decline in older adults, amyloid plaques, β-cleavage, amyloidogenic peptides, genetic risk, Icelandic population
- MeSH terms
- Aging, Alleles, Alzheimer Disease, Cognition, Cognition Disorders, Humans, Mutation, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Amyloid Precursor Protein Secretases, HEK293 Cells, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.